BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
VivoSim Labs, Inc. Common Stock
VIVS
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
Valuation
- Market capitalization
- $2.43M
- Price / earnings
- —
- Price / book
- 0.34×
- Price / sales
- 18.03×
- EV / sales
- -45.41×
- EV / EBITDA
- 0.52×
Profitability
- Earnings per share
- -$0.51
- Return on assets
- -103.47%
- Return on equity
- -141.78%
- Dividend yield
- 0%
Liquidity and leverage
- Debt / equity
- 0×
- Current ratio
- 3.5×
- Quick ratio
- 3.49×
- Cash ratio
- 3.19×
Cash flow
- Price / cash flow
- —
- Price / free cash flow
- —
- Free cash flow
- -$10.29M
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q2 FY2027 Sep 30, 2026 | Q1 FY2027 Jun 30, 2026 | Q4 FY2026 Mar 31, 2026 | Q3 FY2026 Dec 31, 2025 | Q2 FY2026 Sep 30, 2025 | Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $51K | $18K | $40K | $26K | $28K | $37K |
| Cost of revenue | $56K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | -$5K | $18K | $40K | $26K | $28K | $37K |
| Selling, general and administrative | $2.22M | $1.65M | $2.1M | $1.64M | $1.74M | $1.95M |
| Research and development | $1.1M | $1.13M | $1.13M | $1.14M | $923K | $1M |
| Total operating expenses | $3.31M | $2.78M | $3.23M | $2.78M | $2.66M | $2.95M |
| Operating income | -$3.32M | -$2.76M | -$3.19M | -$2.75M | -$2.64M | -$2.92M |
| Interest expense | $0 | -$4K | -$4K | -$4K | $0 | -$4K |
| Income before taxes | -$475K | -$1.34M | -$5.76M | -$2.69M | -$2.54M | -$2.84M |
| Income taxes | $0 | $3K | $0 | $0 | $2K | $0 |
| Net income | -$475K | -$1.34M | -$5.76M | -$2.69M | -$2.55M | -$2.84M |
| Net income attributable to common shareholders | -$475K | -$1.34M | -$5.76M | -$2.69M | -$2.55M | -$2.84M |
| EBITDA | -$3.28M | -$2.72M | -$3.14M | -$2.7M | -$2.58M | -$2.85M |
| Basic earnings per share | -$0.03 | -$0.25 | -$2.19 | -$1.03 | -$0.98 | -$1.14 |
| Diluted earnings per share | -$0.03 | -$0.25 | -$2.19 | -$1.03 | -$0.98 | -$1.14 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.